⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151244 | 1.00 | — | — | |
| SCHEMBL8917932 | 1.00 | — | — | |
| SCHEMBL18341554 | 0.76 | — | — | |
| SCHEMBL14890206 | 0.76 | — | — | |
| SCHEMBL727656 | 0.76 | — | — | |
| SCHEMBL1320186 | 0.74 | — | — | |
| SCHEMBL24939564 | 0.73 | — | — | |
| SCHEMBL888890 | 0.73 | — | — | |
| SCHEMBL9538317 | 0.73 | — | — | |
| SCHEMBL22334216 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024533-B2 | Antimicrobial organosilanes | TOPIKOS SCIENTIFIC, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024533-B2 | Antimicrobial organosilanes | TOPIKOS SCIENTIFIC, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20160159819-A1 | CHEMICAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2016-06-09 | — | — | US | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| EP-1903021-B1 | PROCESS FOR PRODUCTION OF FLUOROCOMPOUNDS | TOSOH F TECH INC (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-7615669-B2 | Process for producing fluoro-compounds | TOSOH F-TECH, INC. (JP) | 2009-11-10 | — | — | US | disclosed |
| US-20090030228-A1 | Process for producing fluoro-compounds | TOSOH F-TECH, INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1903021-A1 | PROCESS FOR PRODUCTION OF FLUOROCOMPOUNDS | Tosoh F-Tech, Inc. (JP) | 2008-03-26 | — | — | EP | disclosed |